The genetic background of Parkinson's disease and novel therapeutic targets

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. The median age of disease onset is around 60 years. From a genetic point of view, PD is basically considered a sporadic, idiopathic disease, however, hereditary components can be detected in 5-10% of patient...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Salamon András
Zádori Dénes
Szpisjak László
Klivényi Péter
Vécsei László
Dokumentumtípus: Cikk
Megjelent: 2022
Sorozat:EXPERT OPINION ON THERAPEUTIC TARGETS 26 No. 10
Tárgyszavak:
doi:10.1080/14728222.2022.2153037

mtmt:33364386
Online Access:http://publicatio.bibl.u-szeged.hu/25972
LEADER 01945nab a2200265 i 4500
001 publ25972
005 20230203083728.0
008 230105s2022 hu o 0|| Angol d
022 |a 1472-8222 
024 7 |a 10.1080/14728222.2022.2153037  |2 doi 
024 7 |a 33364386  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a Angol 
100 1 |a Salamon András 
245 1 4 |a The genetic background of Parkinson's disease and novel therapeutic targets  |h [elektronikus dokumentum] /  |c  Salamon András 
260 |c 2022 
300 |a 827 -836 
490 0 |a EXPERT OPINION ON THERAPEUTIC TARGETS  |v 26 No. 10 
520 3 |a Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. The median age of disease onset is around 60 years. From a genetic point of view, PD is basically considered a sporadic, idiopathic disease, however, hereditary components can be detected in 5-10% of patients. Expanding data are available regarding the targeted molecular therapy of the disease.The aim of this current review article is to provide brief clinical and molecular insight into three important genetic forms (LRRK2, SNCA, GBA) of hereditary PD subtypes and to present the human clinical trials in relation to these forms of the disease.These small hereditary subgroups are crucially important in drug development, because the general trend is that clinical trials that treat PD patients as a large group, without any separation, do not meet expectations. As a result, no long term conclusions can currently be drawn regarding the effectiveness of the molecules tested in these phase 1 and 2 studies. Further precise studies are needed in the near future. 
650 4 |a Klinikai orvostan 
700 0 1 |a Zádori Dénes  |e aut 
700 0 1 |a Szpisjak László  |e aut 
700 0 1 |a Klivényi Péter  |e aut 
700 0 1 |a Vécsei László  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/25972/7/33364386.pdf  |z Dokumentum-elérés